PPARA and metabolic dysfunction-associated steatotic liver disease: These results were confirmed in a clinical study [44], where PPARα was found to be downregulated in the liver of NAFLD patients; thus, PPARα agonists can be regarded as possible molecules for the treatment of NAFLD.